Prostate cancer (PCa) is an increasingly prevalent health problem in the developed world.
Effective treatment options exist for localized PCa, but metastatic PCa has fewer treatment …

Simple Summary Androgen receptor (AR) signaling mainly controls prostate cancer (PCa)
growth. Hence, the conventional regimen for PCa includes androgen deprivation therapy …

Prostate cancer is initially regulated by the androgen receptor (AR), a ligand-activated,
transcription factor, and is in a hormone-dependent state (hormone-sensitive prostate …

Cisplatin-based combination chemotherapy is the foundation for treatment of advanced
bladder cancer (BlCa), but many patients develop chemoresistance mediated by increased …

Epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2
(HER2) protein tyrosine kinases co-expressed in various cancers such as ovarian, breast …

Castration-resistant prostate cancer (CRPC) continues to be a major clinical problem and its
underlying mechanisms are still not fully understood. The epidermal growth factor receptor …

Simple Summary Advanced prostate cancer is often drug resistant and requires new
treatment strategies. Lysosomoptropic agents selectively target lysosomes in cancer cells …

The lesson from many studies investigating the efficacy of targeted therapy in glioblastoma
(GBM) showed that a future perspective should be focused on combining multiple target …

Androgen deprivation therapy (ADT) is a systemic therapy for advanced prostate cancer
(PCa). Although most patients initially respond to ADT, almost all cancers eventually …

Oncologic disease is a significant global health issue that causes thousands of deaths
annually, and it has a significant impact on the quality of life of patients. Prostate cancer …